Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: Systematic review and meta-analysis

BMJ (Online)

Volumn 345, Issue 7881, 2012, Pages

  Low, Emma V ^a   Avery, Anthony J ^b   Gupta, Vaibhav ^b   Schedlbauer, Angela ^b   Grocott, Michael P W ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; GINKGO BILOBA EXTRACT; PLACEBO; SPIRONOLACTONE;

ALTITUDE; ALTITUDE DISEASE; ARTICLE; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DYSGEUSIA; HUMAN; LOW DRUG DOSE; META ANALYSIS; MICTURITION DISORDER; PARESTHESIA; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACETAZOLAMIDE; ACUTE DISEASE; ALTITUDE SICKNESS; BIAS (EPIDEMIOLOGY); CARBONIC ANHYDRASE INHIBITORS; DATABASES, BIBLIOGRAPHIC; HUMANS; MOUNTAINEERING; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84868327829     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e6779     Document Type: Article

References (43)

1. Salisbury R, Hawley E. The Himalaya by the numbers: a statistical analysis of mountaineering in the Nepal Himalaya. Vajra, 2011.
2. Hunt L. Mount Kilimanjaro: climb and punishment. Telegraph Travel, 2010.
3. Imray C, Booth A, Wright A, Bradwell A. Acute altitude illnesses. BMJ 2011;343:d4943.
4. Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollague (3696 m) in northern Chile. Wilderness Environ Med 2007;18:251-7.
5. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol 2003;4:45-52.
6. Kayser B, Hulsebosch R, Bosch F. Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alti Med Biol 2008;9:15-23.
7. Joint Formulary Committee. British National Formulary. BMA, RPS 2011. (No 61.)
8. Bailey DM, Davies B. Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2001;2:21-9.
9. Gertsch JH, Seto TB, Mor J, Onopa J. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 2002;3:29-37.
10. Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med 1996;67:445-52.
11. Hussain MM, Aslam M, Khan Z. Acute mountain sickness score and hypoxemia. J Pak Med Assoc 2001;51:173-9.
12. Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000;321:267-72.
13. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 2004;328:797.
14. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;107-14.
15. Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP. Acetazolamide mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 2006;7:17-27.
16. Roach RC, Bärtsch P, Hackett PH, Oelz O, Committee. LLASC. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Coates G, Huston CS, eds. Hypoxia and molecular medicine: proceedings of the 8th international hypoxia symposium. Queens City Printers 1993;272-4.
17. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Cochrane Collaboration 2011.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;557-60.
20. Olzowy M. Prevention of altitude sickness. Fortschr Med 1975;93:1415-22.
21. Utz G, Schlierf G, Barth P, Linhart P, Wollenweber J. Prevention of acute mountain sickness using acetazolamide. Munch Med Wochenschr 1970;112:1122-4.
22. Basnyat B, Hargrove J, Holck PS, Srivastav S, Alekh K, Ghimire LV, et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol 2008;9:209-16.
23. Basnyat B, Holck PS, Pun M, Halverson S, Szawarski P, Gertsch J, et al. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ Med 2011;22:15-22.
24. Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:296-301.
25. Gertsch JH, Lipman GS, Holck PS, Merritt A, Mulcahy A, Fisher RS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med 2010;21:236-43.
26. Van Patot MCT, Leadbetter G 3rd, Keyes LE, Maakestad KM, Olson S, Hackett PH. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol 2008;9:289-93.
27. Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976;2:1149-55.
28. Larson EB, Roach RC, Schoene RB, Hornbein TF. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 1982;248:328-32.
29. Burki NK, Khan SA, Hameed MA. The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest 1992;101:736-41.
30. Seupaul RA, Welch J, Malka S, Emmett T. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Ann Emerg Med 2012;59:307-17.
31. Kayser B, Dumont L, Lysakowski C, Combescure C, Haller G, Tramer MR. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol 2012;13:82-92.
32. Bradwell AR, Burnett D, Davies F. Acetazolamide in control of acute mountain sickness. Lancet 1981;1:180-3.
33. Carlsten C, Swenson ER, Ruoss S. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol 2004;5:33-9.
34. Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 1987;83:1024-30.
35. Fischer R, Lang SM, Leitl M, Thiere M, Steiner U, Huber RM. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 2004;23:47-52.
36. Greene MK, Kerr AM, McIntosh IB, Prescott RJ. Acetazolamide in prevention of acute mountain sickness: a double-blind controlled cross-over study. BMJ 1981;283:811-3.
37. Hillenbrand P, Pahari AK, Soon Y, Subedi D, Bajracharya R, Gurung P, et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial. Wilderness Environ Med 2006;17:87-93.
38. Kronenberg RS, Cain SM. Hastening respiratory acclimatization to altitude with benzolamide (CL 11,366). Aerospace Med 1967;39:296-300.
39. Zell SC, Goodman PH. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med 1988;148:541-5.
40. Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991;154:289-93.
41. Nicholson AN, Smith PA, Stone BM, Bradwell AR, Coote JH. Altitude insomnia: studies during an expedition to the Himalayas. Sleep 1988;11:354-61.
42. Reinhart WH, Goerre S, Barstch P. Acetazolamide reduces the erythropoietin response to hypoxia at high altitude in humans. J Wilderness Med 1994;5:312-7.
43. Banderet LE. Self-rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviation Space Environ Med 1977;48:19-22.